Kevin Flanigan
Program Director · Nationwide Children's Hospital
Credentials: · · ·
History
Research
Evidence-based path to newborn screening for Duchenne muscular dystrophy
Annals of Neurology · 2012 · 669 citations
Eteplirsen for the treatment of Duchenne muscular dystrophy
Annals of Neurology · 2013 · 617 citations
The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations
Human Mutation · 2015 · 571 citations
41 papers
26 papers · 1 as a fellow
22 papers
20 papers
16 papers
14 papers
12 papers
- KM
12 papers
Grants
- 2026–2031
Training Program in Basic and Translational Gene Therapy Research
National Institute of Neurological Disorders and Stroke · T32
Contact PI · $351.7K · Research Inst Nationwide Children's Hosp
- 2024–2028
MDSRC for Next Directions in Muscular Dystrophy Research
National Institute of Child Health and Human Development · P50
Contact PI · $4.6M · Research Inst Nationwide Children's Hosp
- 2023–2027
Molecular Mechanisms of Dystrophin Expression in Ameliorated Phenotypes
National Institute of Neurological Disorders and Stroke · R01
Contact PI · $1.8M · Research Inst Nationwide Children's Hosp
- 2014–2027
Genetic Modifiers of Duchenne Muscular Dystrophy
National Institute of Neurological Disorders and Stroke · R01
Contact PI · $8.6M · Research Inst Nationwide Children's Hosp
Clinical trials
- 2021–2025
- 2020–2023
Principal investigator · Completed · Phase 2
Kevin Flanigan
- 2018–2021
Spironolactone Versus Prednisolone in DMD
Principal investigator · Terminated · Phase 1
Kevin Flanigan
- 2017–2023
Gene Transfer Clinical Trial to Deliver rAAVrh74.MCK.GALGT2 for Duchenne Muscular Dystrophy
Principal investigator · Completed · Phase 1, Phase 2
Kevin Flanigan